Kornimate/medical-research-clean huggingface dataset:
comparison of walking parameters between idiopathic toe walking and independent walking diparetic cerebral palsy

Conditions: Gait Disorders in Children; Cerebral Palsy Spastic Diplegia

Summary: the aim of the observational study is to compare static, kinematic and kinetic parameters with normal gait parameters in cases with idiopathic toe walking (itw) and diparetic cerebral palsy (dcp) who have gross motor function classification system 1 level with the 3d gait analysis method, and to enable the early diagnosis of dcp and itw. male and female cases aged between 3-18 years will be included. this study will be carried out at acıbadem altunizade hospital.

it is an observational study. the aim of the observational study is to compare static, kinematic and kinetic parameters with normal gait parameters in cases with idiopathic toe walking (itw) and diparetic cerebral palsy (dcp) who have gross motor function classification system 1 level with the 3d gait analysis method, and to enable the early diagnosis of dcp and itw. male and female cases aged between 3-18 years will be included. this study will be carried out at acıbadem altunizade hospital. 51 cases will be included in our study. these cases will be divided into three groups. the first group will consist of patients diagnosed with idioaptic toe walking (n:17), the second group will be composed of diparetic cerebral palsy (n:15) with independent ambulation, and the third group will be the control group (n:19). first, the demographic information of the cases will be recorded. with 3d walking analysis, kinetic, kinematic and static data will be collected. the analysis of the obtained data will be done with polygon software (vicon, oxford, uk). evaluated kinetic, kinematic and static parameters will be compared between three groups. is the lower extremity compensation of children with diparetic cerebral palsy who can walk independently more than children with idiopathic toe walking?

Eligibility criteria:
inclusion criteria: * voluntary consent from family * diagnosed with idiopathic toe walking and spastic diparesis between the ages of 3-18. * cases with gmfcs 1 * the patients who applied to the healthy children's clinic, showed typical development, did not have any musculoskeletal and neurological problems, and wished to voluntarily participate in the study were included in the control group. exclusion criteria: * refusing to participate in the study * under the age of 3 and over the age of 18 * not at gmfcs 1 level * cases who did not have any orthopedic problems other than accompanying toe walking were excluded from the study.

Keywords: toe walking cerebral palsy idiopathic toe walking 3d gait analysis
comparison of clinical outcomes of distal radius fractures treated surgically with walant and peripheral nerve block

Conditions: Distal Radius Fracture

Summary: walant anesthesia technique has been frequently preferred in hand and upper extremity surgery in recent years. walant technique; it stands out with its advantages such as lack of pre-operative anesthesia preparation process, reduction in test and examination requests, reduction in unnecessary hospitalizations and high patient satisfaction. there are studies with a high level of evidence showing that the walant technique has such advantages in soft tissue and smallmedium bone fracture surgery. in large bone fractures (radius, etc.), surgical treatment is performed with the walant technique and positive results have been reported. although there is a study comparing walant and general anesthesia in the surgical treatment of distal radius fractures, there is no study comparing the peripheral nerve block technique.


Eligibility criteria:
inclusion criteria: * patients older than 18 years of age * patients who had acute distal radius fracture which underwent surgery exclusion criteria: * patients with open fractures * additional injuries in the same extremity, peripheral vascular disease, and local anesthetic allergy at the time of first admission * patients who are switched to general anesthesia after both techniques * patients who underwent a second surgery on the same extremity due to any complication * patients who had lacked follow-up examination information

Keywords: walant distal radius fracture peripheral nerve block
response to intermittent pneumatic compression therapy in head and neck cancer-related lymphedema

Conditions: Head and Neck Neoplasms; Head and Neck Lymphedema; Head and Neck Cancer

Summary: assessment of lymphatic structure and function pre- and post- treatment and during recovery in head and neck cancer related lymphedema patients using nir fluorescence lymphatic imaging: response to icd therapy in hnc patients.

a non-randomized, non-blinded, single site pilot study designed to assess whether near-infrared fluorescence imaging can report on the efficacy of a pneumatic compression device to move lymph in head and neck cancer survivors with resulting head and neck lymphedema.

Eligibility criteria:
inclusion criteria: * participants must be 18 years of age or older * participants must be diagnosed with lymphedema of the head and/or neck * participants must be diagnosed with squamous cell carcinoma of the oral cavity, oropharynx or larynx and underwent surgery and radiation as part of their standard-of-care treatment plan. * participants must be ≥ 4 weeks post-radiation therapy * female participants of childbearing potential must have a negative urine pregnancy test ≤ 36 hours prior to study drug administration * female participants of childbearing potential must agree to use a medically accepted method of contraception for a period of one month after each imaging session * participants must be willing to use the flexitouch® system at home daily for two (2) weeks exclusion criteria: * women who are pregnant or breast-feeding * persons who are allergic to iodine * a female of child-bearing potential, who does not agree to use an approved contraceptive for one month after study participation * persons who do not meet inclusion criteria * persons with pulmonary edema, thrombophlebitis, congestive heart failure, deep vein thrombosis, episodes of pulmonary embolism, infections and inflammation, or acute cancer * persons with uncontrolled hyperthyroidism or parathyroidism (for with an endocrinologist recommends against neck compression) * carotid sinus hypersensitivity syndrome * symptomatic carotid artery disease, as manifested by a recent transient ischemic attack (within 30 days), ischemic stroke, or amaurosis fugax (monocular visual ischemic symptoms or blindness) * symptomatic bradycardia in the absence of a pacemaker * internal jugular venous thrombosis, acute or within 3 months * known intracranial pressure or other contraindication to internal or external jugular venous compression * acute radiation dermatitis, unhealed surgical scar, unhealed or open wound(s), surgical flap less than 6-8 weeks post-operative * facial or head and neck dermal metastasis * acute facial infection (e.g., facial or parotid gland abscess) * any condition where increased venous and lymphatic return is undesirable

Keywords: lymphedema cancer head cancer neck cancer
retrospective analysis on distal humerus fractures

Conditions: Distal Humerus Fracture

Summary: the purpose of this study is to evaluate preoperative objective measurements for distal humerus orif patients and operative objective measurements to determine if there is any effect to postoperative outcomes. patients who were 18 years old or greater at the time of surgery were followed clinically and radiographically to determine best practice and optimal treatment and technique, risk and rate of complication, and postoperative outcomes.


Eligibility criteria:
inclusion criteria: 1. english speaking 2. \>18 years of age 3. open reduction internal fixation surgical management of a distal humeral fracture performed by principal investigator at st. elizabeth healthcare exclusion criteria: 1. non-english speaking 2. \<18 years of age
non invasive study of the hepatic fibrosis in paediatrics by the method of study of pediatric hepatic fibrosis

Conditions: Cirrhosis; Liver Fibrosis; Portal Hypertension; Cystic Fibrosis; Cholestasis of Parenteral Nutrition

Summary: early diagnosis of liver fibrosis is useful for the follow-up and treatment of chronic liver disease. at present, the unique validated method to evaluate the liver fibrosis in children, is the liver biopsy which is an invasive method. if the elastometry method is proved to be a good method to evaluate the fibrosis in children, a numerous liver biopsy could be avoided.

the elastometry method is proved to be efficient for the evaluation of liver fibrosis in adults. but the inter-costal space is too thin in children, and the adult probe could not be used. recently a special probe adapted to the children have been technicated. we want to test this specific probe in children. five french paediatrics centres will participate to the study. we need 200 children inclusions in 2 years to have a statistically power analysis. inclusion of each child will be in order to the need of a liver biopsy. each children included will have an elastometry measure in the same time than the liver biopsy. the fibrosis will be staged by a trained pathologist and scored by metavir score witch is the reference. the elastometry measure will be realised by physician with 3 sequential measures in each child. the statistical analysis will be performed by statistician. if elastometry is proved to be an efficient method to evaluate the liver fibrosis in children, a numerous of liver biopsy could be avoided. because elastometry is a non invasive method it could also be used as follow-up in different categories of children who needs sequential liver biopsy.

Eligibility criteria:
inclusion criteria : * children age more than 6 months and under 18 years old. * children with an hepatic biopsy for any fibrosis hepatitic diseases * clinical examination by a physician exclusion criteria : * children of less than 6 months and more than 18 years old. * pregnant women. * no written informed consent * no social security

Keywords: liver fibrosis elastometry fibroscann children
bromocriptine quick release (bcqr) as adjunct therapy in type 1 diabetes

Conditions: Type 1 Diabetes

Summary: type 1 diabetes (t1d) continues to be a disease plagued by hyperglycemia, insulin resistance (ir), and increased cardiovascular disease (cvd) despite advances in insulin delivery and glucose monitoring. therefore new approaches are needed. bromocriptine (bc), a dopamine (da) agonist, has long been widely used for treating parkinson's disease and prolactinoma. its recent approval in a quick release formulation, bcqr, for type 2 diabetes (t2d) is an exciting development, representing a novel mechanism for improving ir. bcqr has not been studied in t1d, but it's mechanism of action, mechanistic studies, and preliminary data support the proposed study of possible benefits of bcqr on insulin action, glycemic control, and the vasculature in t1d. this study has received an exemption from the fda to study bcqr in adults with t1d and an ind approval (131360) to study bcqr in adolescents with t1d. this is a random-order, double-blind, placebo-controlled study of a 4 week intervention. outcomes will include fasting and postprandial glucose, glycemic variability, insulin dosing, hypoglycemia frequency and awareness, sleep quality, and metabolic hormone levels.


Eligibility criteria:
inclusion criteria: 1. type 1 diabetes (t1d) of \>1 year duration based on a clinical course consistent with t1d and rapid conversion to insulin requirement after diagnosis. 2. hba1c 6.5-10% (adults) or any hba1c up to 12% (pediatrics) 3. age 12-60 years of age exclusion criteria: 1. any comorbid condition associated with inflammation, insulin resistance, or dyslipidemia including cancer, heart failure, active or end stage liver disease, kidney disease (except microalbuminuria), inadequately treated thyroid disease, or rheumatologic disease; 2. tobacco or marijuana use; 3. pregnancy; 4. regular or frequent oral steroid use; 5. current use of insulin sensitizing medications, neuroleptics, ergot-related medications, or triptan medications for migraine, 6. diagnosis or history of psychosis, 7. diabetes of other cause such as maturity onset diabetes of the young or cystic fibrosis-related diabetes.
effects of tt301 on cytokine levels post endotoxin challenge

Conditions: Traumatic Brain Injury

Summary: this study will evaluate the effects of tt301 on cytokine levels in healthy male volunteers participating in an endotoxin challenge.

the lps human endotoxemia model results in a well characterized, transient acute inflammatory response. the model has been widely used for decades as a system to study new therapeutic agents for inflammation before wider clinical studies are undertaken. this study will evaluate the effects of tt301 on cytokine levels in healthy male volunteers participating in an endotoxin challenge.

Eligibility criteria:
inclusion criteria: * male * 18 to 40 years, inclusive * 55 - 95 kg, inclusive exclusion criteria: * evidence of any clinically significant disease * history of cancer * history of syncope or severe vasovagal events * antibiotic treatment within 60 days of day 1 * surgical procedure within 60 days of day 1 * hepatitis c, hepatitis b * tuberculosis * hiv * requirement for medications (prescription/otc) during the study * donated \> 250 ml blood within 30 days of day 1 * donated \> 750 ml blood within 60 days of day 1 * in a clinical trial of an immunosuppressive drug within 6 months of day 1 * received any vaccination within 6 months of day 1 * any clinically important allergy * known allergy/sensitivity to lactose and/or polyethylene glycol
cerebral toxoplasmosis and aids

Conditions: Cerebral Toxoplasmosis; AIDS

Summary: with a hiv incidence much higher in the dfa than in european french territory, this disease is a major public health problem in these areas, especially in french guiana. cerebral toxoplasmosis is a priority among the opportunistic infections in aids patients from the dfa because of its frequency (french west indies) and of its lethality (french guiana). the diagnosis of cerebral toxoplasmosis may be difficult because based only on presumptive clinical and radiological features. the response to specific antitoxoplasmic therapy confirms a posteriori the diagnosis. in reference to the data collected by the biological resource centre toxoplasma, in particular in french guiana, we think that t. gondii strains reactivating in aids patients from dfa are genetically different from those reactivating in aids patients from europe, with an increased capacity for dissemination via peripheral blood in the first ones. this more frequent or more prolonged parasitemia could facilitate the diagnosis of cerebral toxoplasmosis by pcr test from peripheral blood samples in aids patients from the french departments of america.


Eligibility criteria:
inclusion criteria: * adult patient (\> 18 years) * patient being informed and accepting to participate in the study with signature of informed consent * hiv positive serology * clinical and radiological suspicion of cerebral toxoplasmosis justifying the start of specific antitoxoplasmic therapy exclusion criteria: * protected patient * patient uncovered by social insurance * specific antitoxoplasmic therapy already initiated since 72h or more
powerful tools for caregivers of dementia patients

Conditions: Caregivers; Dementia; Alzheimer Disease

Summary: the purpose of this study is to examine if a psycho-educational intervention for caregivers of patients with dementia will decrease caregiver burden, increase caregiver physical activity, and decrease the reporting of behavioral and psychological symptoms of the person with dementia.


Eligibility criteria:
inclusion criteria: * caregiver lives with or provides care for the care recipient for an average of at least 4 hours per day. * care for an individual with a physician diagnosis of dementia (mild to moderate stage of dementia). * care for a care recipient who experiences behavioral symptoms that bother or upset the caregiver moderately, very much, or extremely. the occurrence of problematic behaviors and caregivers' reactions will be assessed with 6-items adapted from the revised memory and behavior problems checklist (teri et al 1992). exclusion criteria: * care for a care recipient who is bed-bound or has advanced dementia: functional assessment staging (fast)(sclan \& reisberg 1992) stage 7. * caregiver's cognitive, hearing, visual, or other physical impairments lead to difficulty with informed consent process, assessment, or participation in the intervention. * caregiver who is involved in another trial that addresses caregiver burden or behavioral expressions.

Keywords: caregivers behavioral symptoms dementia alzheimer disease physical activity depressive symptoms powerful tools for caregivers chronic disease self-management program
answering questions about vitamin d supplementation and sun exposure in patients who have undergone surgery for stage ib, stage ii, or stage iiia melanoma

Conditions: Melanoma (Skin)

Summary: rationale: gathering information about vitamin d supplementation and sun exposure in patients with melanoma may help doctors learn more about the disease and find what may affect cancer relapse. purpose: this clinical trial is studying vitamin d supplementation and sun exposure in patients who have undergone surgery for stage ib, stage ii, or stage iiia melanoma.

objectives: * to examine the findings of the pilot study, that vitamin d supplementation in combination with vitamin d receptor (vdr) polymorphisms protects from late relapse (after 3 years) in patients who have had melanoma. * to investigate the effects of vitamin d supplement dosage in reducing the risk of late relapse. * to examine if vitamin d supplementation in combination with particular vdr polymorphisms protects from early relapse (before 3 years). * to examine if serum levels of vitamin d correlate with risk of relapse in groups of patients with different vdr polymorphisms. * to examine the effect of vitamin supplementation and vdr status on time to relapse and survival in these patients. * to examine other factors that may affect risk of relapse by assembling a tissue (genomic dna and serum) resource. * to investigate the effect of exposure to incidental drugs, such as statins, on risk of relapse in these patients. outline: patients are stratified according to disease relapse in the past 5 years (yes vs no). patients are asked to complete a food frequency questionnaire focusing on vitamin d and the following area: supplementation of diet with vitamins/fish oil and duration of use; sun exposure and sunscreen-use per decade prior to and after diagnosis. patients are also asked to provide a blood sample for serum and dna analysis. consenting patients are also tagged with the office of national statistics to allow passive follow up. stored tissue from the patient's primary melanoma may be used to corroborate research findings using immunohistochemistry or studies of gene expression, polymorphism, or mutation.

Eligibility criteria:
disease characteristics: * diagnosed with melanoma * must meet either of the following conditions: * resected stage ib, ii, or iiia disease that has relapsed as either stage iii or iv disease (cases) * first loco regional and/or visceral relapse (with/without sentinel node biopsy) * no more than 3 months since first relapse * resected stage ib, ii, or iiia disease that has not relapsed for ≥ 5 years (controls) patient characteristics: * not specified prior concurrent therapy: * see disease characteristics

Keywords: recurrent melanoma stage ib melanoma stage ii melanoma stage iiia melanoma
effect of antidepressants on white matter structure

Conditions: Major Depression

Summary: subjects with major depression will be evaluated and intensively characterized through questionnaires, computerized cognitive evaluation and laboratory investigations. magnetic resonance imaging will be used to document baseline white matter structure. subjects will then receive desvenlafaxine which will be adjusted as clinically indicated. after 16 weeks the evaluations will be repeated.

40 subjects will be included in the study. diagnosis will be confirmed by mini. participants will be characterised using questionnaires, pain threshold, cognition, facial expression recording and mri. desvenlafaxine will be initiated at 50mg am. at week 8 desvenlafaxine may be increased to 100mg as clinically indicated. measures will be repeated at the end of the study.

Eligibility criteria:
inclusion criteria: * major depression * age 18 to 55 * hamilton grater or equal to 20 exclusion criteria: * major neurologic disorder * major cardiovascular disorder * unstable medical condition * significant psychiatric co-morbidity * current substance dependance * pregnancy or lactation -treatment resistance as defined by nonresponse to 2 or more antidepressant treatments (adequate dose and duration) -

Keywords: major depression dti inflammatory markers cognition
new therapeutic perspectives in obesity

Conditions: Obesity;

Summary: obesity is a chronic disease of increasing prevalence, being currently considered a global epidemic, including children, adolescents, adults and the elderly of different nationalities and ethnicities, socioeconomic levels, education levels. non-pharmacological therapeutic interventions, such as physical exercise and fitness healthy eating strategies seem to be increasingly studied and recommended for healthy weight loss. in addition, therapies that can complement the effect of exercise and diet for reducing body weight are considerate important strategies. thus, experimental evidence shows that the use of laser therapy combined with exercise swimming was effective in controlling the lipid profile, reducing the mass of adipose tissue, suggesting increased metabolic activity and changes in lipid metabolism. to investigate the effect of the use of therapeutic laser when associated to exercise like response to new therapy for weight loss and decrease of dyslipidemias levels.

methods: during 20 weeks, each patients will receive 3 session of exercise with duration of 1 hour. each session of exercise will composed of aerobic exercise and resistence exercise. after training session, each patient will receive application of phototherapy during 16 minutes. the protocol of phototherapy appplication is described in link "interventions"

Eligibility criteria:
inclusion criteria: * volunteers aged 20-40 years with a body mass index (bmi) ≥ 30 above, of both genders with primary obesity; exclusion criteria: * the criteria for inclusion are volunteers who use contraceptive use, cortisone, anti-epileptic drugs, history of kidney and heart disease, alcohol abuse, smoking, use of supplemental vitamins or secondary diagnosis of obesity. after the pre-selection in the initial interview, the volunteers who contemplate all the inclusion criteria will be referred for clinical evaluation with an interdisciplinary health team and the electrocardiogram stress test to verify the release of the practice of physical exercises proposed by the project .

Keywords: anthropometric parameters; biochemical parameters; inflammatory markers neuropeptide markers phototherapy